


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31199966</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1527-9995</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jun</Month>
                        <Day>11</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Urology</Title>
                <ISOAbbreviation>Urology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A PROSPECTIVE STUDY TO EVALUATE EFFICACY USING THE NURO™ PERCUTANEOUS TIBIAL NEUROMODULATION SYSTEM IN DRUG-NAÏVE PATIENTS WITH OVERACTIVE BLADDER SYNDROME (OAB).</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S0090-4295(19)30527-8</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.urology.2019.06.002</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate changes from baseline in urgency urinary incontinence (UUI) episodes, urinary frequency (UF) and quality of life through 12 weeks of percutaneous tibial neuromodulation (PTNM) therapy using NURO in drug-naïve OAB subjects.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Eligible subjects underwent 12 weekly PTNM sessions with the NURO system. Changes in voiding symptoms were evaluated with bladder diaries from baseline through 12 weeks. Analyses were conducted for subjects with data at baseline and follow-up visits (sessions 1, 4, 8, and 12). Safety was evaluated through adverse events (AE) related to the device, procedure and therapy.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 154 subjects enrolled in the study,120 subjects met study criteria and received PTNM. The mean age was 64.8 years, mean duration of OAB diagnosis was 3.4 years and 86% female subjects. No subjects tried OAB medication prior to enrollment. At baseline, patients had 3.5±2.5 (mean ± SD) UUI episodes/day. Statistically significant improvement in UUI episodes from baseline was observed at each follow-up visit (p&lt;0.0001), with a reduction of 2.4±2.1 episodes after session 12 from baseline. Subjects with UF at baseline had 11.5±2.9 voids/day. After session 12, a statistically significant reduction of 1.7±2.5 voids/day was observed (p&lt;0.0001). Ninety-six percent (116/120) of subjects completed the study with diary data for the primary objective with an average of 11.6 sessions. There were no serious or unanticipated AEs. The most common AEs were medical device site pain (3.3%, 4/121) and extremity pain (3.3%, 4/121).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">PTNM using NURO is an effective and safe treatment for drug-naïve patients with OAB.</AbstractText>
                <CopyrightInformation>Copyright © 2019. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kobashi</LastName>
                    <ForeName>Kathleen</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Virginia Mason Medical Center. Electronic address: Kathleen.Kobashi@virginiamason.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nitti</LastName>
                    <ForeName>Victor</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>David Geffen School of Medicine at UCLA. Electronic address: VNitti@mednet.ucla.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Margolis</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Urologic Research and Consulting LLC. Electronic address: emargomd@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sand</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>NorthShore University Health-System. Electronic address: peterksand@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Siegel</LastName>
                    <ForeName>Steven</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Minnesota Urology. Electronic address: SSiegel@mnurology.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Khandwala</LastName>
                    <ForeName>Salil</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Advanced Urogynecology of Michigan PC. Electronic address: salil@augm.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Newman</LastName>
                    <ForeName>Diane</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Urology, Penn Medicine, University of Pennsylvania. Electronic address: Diane.Newman@uphs.upenn.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>MacDiarmid</LastName>
                    <ForeName>Scott A</ForeName>
                    <Initials>SA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Alliance Urology Specialists. Electronic address: smacdiarmid@allianceurology.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kan</LastName>
                    <ForeName>Fangyu</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medtronic. Electronic address: fiona.kan@medtronic.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Michaud</LastName>
                    <ForeName>Elizabeth</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medtronic. Electronic address: beth.m.michaud@medtronic.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Urology</MedlineTA>
            <NlmUniqueID>0366151</NlmUniqueID>
            <ISSNLinking>0090-4295</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Overactive bladder</Keyword>
            <Keyword MajorTopicYN="N">overactive bladder drug-naïve</Keyword>
            <Keyword MajorTopicYN="N">percutaneous tibial neuromodulation</Keyword>
            <Keyword MajorTopicYN="N">urgency frequency</Keyword>
            <Keyword MajorTopicYN="N">urinary incontinence</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31199966</ArticleId>
            <ArticleId IdType="pii">S0090-4295(19)30527-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.urology.2019.06.002</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

